Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PAVmed Inc. Director's Dealing 2016

May 23, 2016

35221_dirs_2016-05-23_e3513b75-7ab5-42d9-80d8-fab3d413b350.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PAVmed Inc. (PAVM)
CIK: 0001624326
Period of Report: 2016-05-19

Reporting Person: Aklog Lishan (Director, Chairman and CEO, 10% Owner)
Reporting Person: HCFP/Capital Partners III LLC (10% Owner)
Reporting Person: Pavilion Venture Partners LLC (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-05-19 Common Stock P 1400 Acquired 3400 Direct
2016-05-20 Common Stock P 1700 Acquired 5100 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-05-19 Warrants $5.00 P 1400 Acquired 2022-01-29 Common Stock (1400) Direct
2016-05-20 Warrants $5.00 P 1700 Acquired 2022-01-29 Common Stock (1700) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 5713879 Indirect
Common Stock 2520532 Indirect
Common Stock 87020 Indirect
Common Stock 125000 Indirect
Common Stock 20000 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Warrants $5.00 2022-01-29 Common Stock (5713879) 5713879 Indirect
Warrants $5.00 2022-01-29 Common Stock (12000) 2220532 Indirect
Warrants $5.00 2022-01-29 Common Stock (87020) 387020 Indirect
Warrants $5.00 2022-01-29 Common Stock (125000) 125000 Indirect
Warrants $5.00 2022-01-29 Common Stock (20000) 20000 Indirect

Footnotes

F1: The reporting person purchased units, each unit consisting of one share of the issuer's common stock and one warrant. Each warrant entitles the holder to purchase one share of the issuer's common stock at an exercise price of $5.00 per share, subject to adjustment.The units were purchased at an weighted average price of approximately $9.4387 per unit. These units were purchased in multiple transactions at prices ranging from $8.9998 to $9.60, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of units sold at each separate price within the ranges set forth this footnote to this Form 4.

F2: The reporting person purchased units, each unit consisting of one share of the issuer's common stock and one warrant. Each warrant entitles the holder to purchase one share of the issuer's common stock at an exercise price of $5.00 per share, subject to adjustment.The units were purchased at an weighted average price of approximately $9.3387 per unit. These units were purchased in multiple transactions at prices ranging from $8.50 to $9.60, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of units sold at each separate price within the ranges set forth in Footnote 1 and 3 to this Form 4.

F3: Dr. Aklog is a member and a co-manager of HCFP/Capital Partners III LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.

F4: Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and has sole voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.

F5: Dr. Aklog is a controlling shareholder of HCFP Inc., and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.

F6: Dr. Aklog is a member and a co-manager of the entity that acts as sole manager of HCFP/Capital Partners IIIB LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.

F7: Dr. Aklog is a co-manager of HCFP/AG LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.